A study of more than 750,000 pregnancies found that early exposure to Ozempic, Wegovy, and similar drugs was not linked to increased pregnancy complications when used for weight loss, but was associated with a higher risk of premature birth when prescribed for diabetes. The surprising difference suggests that diabetes itself may be driving the risk, although researchers caution that the drugs' safety during pregnancy remains uncertain.
Study of 750,000 pregnancies reveals a surprising twist about Ozempic and Wegovy
EXECUTIVE SUMMARY
A study of more than 750,000 pregnancies found that early exposure to Ozempic, Wegovy, and similar drugs was not linked to increased pregnancy complications when used for weight loss, but was associated with a higher risk of premature birth when prescribed for diabetes. The surprising difference suggests that diabetes itself may be driving the risk, although researchers caution that the drugs' safety during pregnancy remains uncertain.
Key Takeaways
- Study of 750,000 pregnancies reveals a surprising twist about Ozempic and Wegovy.
- The surprising difference suggests that diabetes itself may be driving the risk, although researchers caution that the drugs' safety during pregnancy remains uncertain.
- The surprising difference suggests that diabetes itself may be driving the risk, although researchers caution that the drugs' safety during pregnancy remains uncertain.
Read Complete Original Article
Published originally on ScienceDaily
